MDLN
Medline Inc.
MDLN's fundamentals are mixed: revenue grew 13%, but its operating margin fell 3 points to 5.7%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
MDLN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Healthy | |
| Weak |
MDLN's profitability and cash flow are currently healthy, but its balance sheet is weak. There isn't enough data to rate its revenue.
MDLN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 33x | $22.09 | -45% |
| Fair | 40x | $27.00 | -32% |
| Expensive | 42x | $28.23 | -29% |
| Current | 60x | $39.98 | — |
Historical ranges are pointers, not guarantees.
MDLN's PE is 60x, but its earnings don't support one, so it isn't a reliable read right now.
MDLN Forward outlook
There aren't enough analyst estimates for MDLN to show an outlook.
MDLN Earnings Per Share
MDLN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $7.9B | +10% |
| Q2 2026 | $7.7B | +12% |
| Q1 2026 | $7.4B | +11% |
| Q3 2025 | $7.1B | +11% |
| Q2 2025 | $6.9B | +11% |
MDLN's revenue has grown year over year every quarter since late 2025: $7.9B last quarter, up 10% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6.4% | -1.7 points |
| Q2 2026 | 5.1% | -4 points |
| Q1 2026 | 5.7% | -3.2 points |
| Q4 2025 | 5.5% | N/A |
| Q3 2025 | 8.1% | -0.9 points |
| Q2 2025 | 9.1% | +0.8 points |
| Q1 2025 | 8.9% | N/A |
| Q3 2024 | 9% | N/A |
MDLN's operating margin was 6.4% last quarter, down 1.7 points from the same quarter a year ago.
MDLN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $884M | +65% |
| Q2 2026 | $604M | +486% |
| Q1 2026 | $316M | -41% |
| Q3 2025 | $535M | -13% |
MDLN's free cash flow has been positive every quarter since late 2024: $2.4B over the past year, up 33% from the year before.
MDLN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +53% | +455M shares |
| 1 year | +67% | +529M shares |
MDLN has 1.3B diluted shares, up 67% from a year ago, despite $2B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | $2B |
| Q3 2025 | $18M |
| Q2 2025 | $3M |
| Q1 2025 | $18M |
| Q3 2024 | $3M |
MDLN spent $2B buying back its own shares over the past year.
MDLN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 4.0x | High |
| Q2 2026 | 3.9x | Elevated |
| Q1 2026 | 3.7x | Elevated |
| Q4 2025 | 3.6x | Elevated |
MDLN's net debt is about 4.0 years of its operating earnings (EBITDA).
MDLN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.9 | Neutral |
| Stochastic | 53.6 | Neutral |
MDLN's weekly RSI is 57 (neutral) and its Stochastic is 54 (neutral).
MDLN PE vs Healthcare Sector
| Metric | MDLN | Sector median | Relative |
|---|---|---|---|
| PE | 60x | 26x | 131% above |
MDLN is trading at 60x earnings, a 131% premium to the Healthcare sector's median of 26x, though its earnings don't support one.
MDLN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $36.1 | 11% above |
| 20 week MA | $36.6 | 9.3% above |
MDLN is in an uptrend: it's above all two of its weekly moving averages, and 9.3% above its 20-week average.
MDLN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $41.7 | $44.1 | +6% |
| 2026 YTD | $44.1 | $40.0 | -9.4% |
MDLN has finished every year since 2025 higher, and it's down 9.4% so far in 2026.